Faculty Opinions recommendation of Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol.

Objective: To compare serum levels of total cholesterol, triglycerides, low density lipoprotein cholesterol and high density lipoprotein cholesterol between broilers and laying hens. Materials and Methods: the present is a cross study, descriptive and analytic. Data was analyzed using simple ANOVA, the program Statgraphics Plus 5.1 was used. The study was performed at Universidad de Caldas in Manizales (Colombia). After fasting, blood from 30 broilers (Cobb 500 line) of 35-day-old and 40 laying hens (Hy-Line W-36 line) of 26-weeks-old. Serum levels of triglycerides, total cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol was measured by enzymatic colorimetric methods, direct method (detergent + N,Nbis (4-sulfobutyl)-m-toluidine) was used for the lipoprotein cholesterol. Results: Between broilers (Cobb 500 line) and (laying hens (Hy-line W-36 line) was significant difference in serum levels of triglycerides and in serum levels of high density lipoprotein cholesterol (P <0.05); serum levels of total cholesterol and serum levels of low density lipoprotein cholesterol, no differences were found (P> 0.05) Conclusions: Despite differences in gender, age, and production system among broilers Cobb 500 line and laying hens Hy-Line W-36, no differences were found between serum total cholesterol and low density lipoprotein cholesterol.

Download Full-text

The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?

Mayo Clinic Proceedings ◽

10.4065/81.9.1225 ◽

2006 ◽

Vol 81 (9) ◽

pp. 1225-1231 ◽

Cited By ~ 11

Author(s):

Terry A. Jacobson

Keyword(s):

Statin Therapy ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Low Density Lipoprotein Cholesterol

Download Full-text

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

European Journal of Preventive Cardiology ◽

10.1177/2047487319864671 ◽

2019 ◽

Vol 27 (6) ◽

pp. 593-603 ◽

Cited By ~ 34

Author(s):

Christie M Ballantyne ◽

Ulrich Laufs ◽

Kausik K Ray ◽

Lawrence A Leiter ◽

Harold E Bays ◽

...

Keyword(s):

Cardiovascular Disease ◽

Statin Therapy ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Low Density ◽

Low Density Lipoprotein Cholesterol ◽

Dose Combination

Aims The aim of this study was to evaluate the low-density lipoprotein cholesterol lowering efficacy and safety of a bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination in patients with hypercholesterolemia and a high risk of cardiovascular disease receiving maximally tolerated statin therapy. Methods This phase 3, double-blind clinical trial enrolled adult patients at high risk of cardiovascular disease due to atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or multiple cardiovascular disease risk factors. Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combination, bempedoic acid 180 mg, ezetimibe 10 mg or placebo added to stable background statin therapy for 12 weeks. The primary efficacy endpoint was the percentage change from baseline to week 12 in low-density lipoprotein cholesterol. Results Among the 301 patients included in the primary analysis, the mean baseline low-density lipoprotein cholesterol level was 3.87 mmol/L (149.8 mg/dL). At week 12, the fixed-dose combination lowered low-density lipoprotein cholesterol (–36.2%) significantly more than placebo (1.8% (placebo-corrected difference –38.0%); P < 0.001), ezetimibe alone (–23.2%; P < 0.001) or bempedoic acid alone (–17.2%; P < 0.001). The fixed-dose combination lowered low-density lipoprotein cholesterol levels similarly across subgroups, including patients receiving high-intensity, other-intensity or no statin therapy. Improvements with the fixed-dose combination were also observed in secondary efficacy endpoints, including high-sensitivity C-reactive protein. In this trial, fixed-dose combination treatment had a generally similar safety profile compared with bempedoic acid, ezetimibe or placebo. Conclusion The bempedoic acid and ezetimibe fixed-dose combination significantly lowered low-density lipoprotein cholesterol versus placebo or other oral monotherapies and had a favourable safety profile when added to maximally tolerated statin therapy in patients with hypercholesterolemia and high cardiovascular disease risk. Trial Registration ClinicalTrials.gov identifier: NCT03337308.

Download Full-text